Cannabis and opioid perceptions, co-use, and substitution among patients across 4 NCI-Designated Cancer Centers.
Rebecca L AshareBrooke WorsterShannon M NugentDanielle M SmithBenjamin J MorascoAmy E LeaderAmy A CaseSalimah H MeghaniPublished in: Journal of the National Cancer Institute. Monographs (2024)
Prescription opioids are used for managing pain in persons with cancer, however, there are socioeconomic and racial disparities in medication access. Cannabis is increasingly used for cancer symptom management and as an opioid alternative. Limited data are available about patterns of opioid and cannabis use among patients with cancer. We used survey data from 4 National Cancer Institute-designated cancer centers in 3 states (n = 1220) to assess perceptions, use of cannabis and opioids for pain, their substitution, and racial and ethnic differences in each outcome. Compared with White patients, Black patients were less likely to use opioids for pain (odds ratio [OR] = 0.66; P = .035) and more likely to report that cannabis was more effective than opioids (OR = 2.46; P = .03). Race effects were mitigated (P > .05) after controlling for socioeconomic factors. Further research is needed to understand cannabis and opioid use patterns and how overlapping social determinants of health create a disadvantage in cancer symptom management for Black patients.
Keyphrases
- chronic pain
- pain management
- papillary thyroid
- end stage renal disease
- healthcare
- ejection fraction
- newly diagnosed
- squamous cell
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- emergency department
- squamous cell carcinoma
- lymph node metastasis
- mental health
- electronic health record
- neuropathic pain
- spinal cord
- cross sectional
- artificial intelligence